Indication: For inotropic support in the short- term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures
Pharmacology: Dobutamine is a direct-acting inotropic agent whose primary activity results from stimulation of the beta-adrenoceptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects. Dobutamine acts primarily on beta-1 adrenergic receptors, with little effect on beta-2 or alpha receptors. It does not cause the release of endogenous norepinephrine, as does dopamine. Dobutamine is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures.
Mechanism Of Action: Dobutamine directly stimulates beta-1 receptors of the heart to increase myocardial contractility and stroke volume, resulting in increased cardiac output.
Drug Category: Cardiotonic Agents; Sympathomimetic; ATC:C01CA07
Brand Names/Synonyms: Dobutamina [Inn-Spanish]; Dobutamine; Dobutamine Hcl; Dobutamine Hcl in Dextrose 5%; Dobutamine Hydrochloride; Dobutamine [Usan:Ban:Inn]; Dobutamine [Usan]; Dobutaminum [Inn-Latin]; Dobutrex; Inotrex; Racemic-Dobutamine
Dosage Forms: LIQUID
Absorption: Not Available
Interactions:
DrugBank: Interactions for Dobutamine
Interactions for Dobutamine:
Animal studies indicate that dobutamine may be ineffective if the patient has recently received a b-blocking drug. In such a case, the peripheral vascular resistance may
increase.
Preliminary studies indicate that the concomitant use of dobutamine and nitroprusside results in a higher cardiac
output and, usually, a lower pulmonary wedge pressure than when either drug is used alone.
There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently
with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate,
isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.
Chemical IUPAC Name: 4-[2-[3-(4-hydroxyphenyl)-1-methyl-propyl]aminoethyl]benzene-1,2-diol
Chemical Formula: C18H23NO3
Half Life: 2 minutes
Drug Type: Approved Drug
# Accession No: APRD00122
CAS Registry Number: 34368-04-2
